Cargando…
Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
Guidelines for the treatment of non-small cell lung cancer adenocarcinoma positive in epidermal growth factor mutations indicate tyrosine kinase inhibitors. There are currently three tyrosine kinase inhibitors that can be used as first line treatment: gefitinib, erlotinib and afatinib. Regarding erl...
Autores principales: | Zarogoulidis, Paul, Rapti, Aggeliki, Sardeli, Chrysanthi, Chinelis, Panagiotis, Athanasiadou, Anastasia, Paraskevaidou, Katerina, Kallianos, Anastasios, Veletza, Lemonia, Trakada, Georgia, Hohenforst-Schmidt, Wolfgang, Huang, Haidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458763/ https://www.ncbi.nlm.nih.gov/pubmed/28616379 http://dx.doi.org/10.1016/j.rmcr.2017.05.013 |
Ejemplares similares
-
“Liquid elbows” due to afatinib administration
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Reduction of exercise capacity in sarcoidosis in relation to disease severity
por: Kallianos, Anastasios, et al.
Publicado: (2015)